arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Fulcrum Therapeutics, Inc.

FULC
$3.89 ▲ +0.12 (+3.05%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
35 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
35
Health
Poor
Neutral
auto_awesome

Analytical Summary

Fulcrum Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $296.7M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -7.5%
FCF / Share $-0.21
Trailing P/E
Price / Book 1.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-18.89M
↓ -7.0%
Operating Margin Operating profit as % of sales
65.6%
↑ +115.6%
FCF / Share Free cash flow per share
$-0.21
↑ +14.0%

Health Breakdown

Returns
27
Cash Quality
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 35 quarters